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T he branched-chain amino acids (BCAAs) leucine, isoleucine, and valine are essential amino acids important for protein synthesis, signaling, and bioenergetics. BCAA catabolism is emerging as a prominently dysregulated pathway in metabolic syndrome 1, 2 and cancer 3 ; as such, a greater and more quantitative understanding of this pathway in mammalian physiology is needed. BCAA catabolism is initiated by deamination via branched-chain amino acid transferases (BCATs), and these branched-chain keto acids are subsequently metabolized in mitochondria to generate various acyl-CoA species downstream of the branched-chain ketoacid dehydrogenase (BCKDH) complex. This pathway is active in both energetically demanding tissues, such as heart and muscle, and lipogenic tissues 4 . Indeed, studies indicate that adipose BCAA catabolism can compensate for whole-body genetic deficiencies in the pathway 5 . Furthermore, carbon from leucine and isoleucine contribute significantly to de novo lipogenesis in differentiated adipocytes 6, 7 , suggesting that adipose tissue BCAA catabolism may be important for adipocyte function.
The predominant product of de novo lipogenesis in mammals is the saturated 16-carbon fatty acid (FA) palmitate, which is further elongated and/or desaturated in a tissue-specific manner. Both oddchain (OCFAs) and monomethyl branched-chain FAs (mmBCFAs) are also present in mammals, but these species are considered to be predominantly diet derived outside of the skin 8, 9 . In lower organisms mmBCFAs are important for controlling membrane fluidity 10 and contribute to neural development 11 . In mammals, mmBCFAs are found in milk 12 , sebum 13 , and vernix 14 , and mmBCFA levels differ in obese and insulin-resistant patients 15, 16 . However, little is known about the metabolism of BCFAs in mammals. Here we demonstrate that mmBCFAs are endogenous products of fatty acid synthase (FASN) and that their in vivo synthesis is influenced by mitochondrial BCAA catabolism, tissue-specific expression of carnitine acetyltransferase (Crat), the microbiome, hypoxia, and diet. mmBCFAs are primarily synthesized in adipose depots and are decreased in the context of diet-induced obesity, in which adipose-specific hypoxia potently suppresses BCAA catabolism and lipogenesis. These results identify a metabolic pathway in mammals connecting BCAA metabolism and lipid biosynthesis to acyl-chain diversity that is coordinated across distinct tissues and potently regulated by hypoxia.
Results

Mammalian adipocytes synthesize mmBCFAs via FASN.
Adipocytes undergo substantial mitochondrial and cytosolic metabolic reprogramming upon differentiation. We and others have previously shown that a distinct feature of this metabolic reprogramming is upregulation of BCAA catabolism, which becomes a substantial source of carbon for both TCA cycle metabolism and lipogenic acetyl-CoA 6, 7, 17 . In cultured adipocytes, odd-chain FAs (C15:0 and C17:0) synthesized from valine-and isoleucine-derived propionyl-CoA can also accumulate as a result of vitamin B12 deficiency and decreased activity of the B12-dependent enzyme methylmalonyl-CoA mutase 6, 7 . In addition to the increased BCAA
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Martina Wallace 1 catabolism and OCFA synthesis observed in differentiated 3T3L1 adipocytes, we detected accumulation of several mass isomers of the FAs C16:0 (palmitate) and C17:0 (heptadecanoate), which eluted before the predominant straight-chain isomers in our gas chromatography-mass spectrometry (GC-MS) analysis. As compromised B12 metabolism can lead to accumulation of monomethyl branched-chain FAs (mmBCFAs) in the brain 18 , we hypothesized that these alternate mass isomers were mmBCFAs and subsequently used analytical standards to confirm their identities. We detected increases in 14-methylpentadecanoate (iso-C16:0), 14-methylhexadecanoate (anteiso-C17:0) and 15-methylhexadecanoate (iso-C17:0) during differentiation of 3T3L1 adipocytes, with iso-C16:0 occurring at the highest abundance (Fig. 1a) . These FAs have a single branch at either the penultimate or antepenultimate carbon of the acyl chain ( Supplementary Fig. 1a) , with the position impacting elution times (Supplementary Table 1 ). Interestingly, the relative abundance of anteiso-C17:0 was impacted by B12 availability in this culture system (Fig. 1b) , suggesting that these species were actively metabolized by adipocytes.
To determine whether mmBCFAs were synthesized de novo, we cultured 3T3L1 adipocytes with [U- 13 C 6 ]glucose, which generates 13 C fully labeled acetyl-CoA units and a distinct M + 2 isotopologue pattern in newly synthesized FAs ( Fig. 1c ; Supplementary  Fig. 1b) . We detected significant enrichment in mmBCFAs ( Fig. 1d ; Supplementary Fig. 1c,d ), demonstrating that these FAs are synthesized in a similar manner to palmitate, via acetyl-CoA incorporation. Additionally, treatment with the ACC inhibitor ND646 (ref. 19 ) led to a significant decrease in 13 C enrichment of both straight-chain FAs and mmBCFAs, indicating that their synthesis is dependent on malonyl-CoA from ACC (Fig. 1e ). H]glucose-labeled NADPH to fatty acid de novo synthesis determined via ISA. 3T3L1 adipocytes cultured in tracer for 72 h. PGD, phosphogluconate dehydrogenase. h, Iso-C16:0 levels as percent total FA in pooled CRISPR-Cas9 FASN KO 3T3L1 adipocytes following addition of isobutyrate for 24 h. i, Relative abundances of mmBCFAs and C16:0 in differentiated 3T3L1s following addition of isobutyrate for 24 h. Two-tailed Student's t-test was performed on three cellular replicates for each comparison with no adjustment for multiple comparisons. All data are presented as means ± s.e.m. with dot plots overlaid except for g, where 95% confidence intervals from ISA model are shown. All data are representative of three cellular replicates, and each experiment was repeated three independent times with the exception of h, for which two separate infections were carried out. The same result was obtained in each independent experiment. *P < 0.05, **P < 0.01, ***P < 0.001.
Although cytosolic FASN is the predominant enzyme used for de novo lipogenesis in mammalian cells, mitochondrial FAS II has been proposed as a hypothetical route for mmBCFA synthesis in eukaryotes 20 . To determine whether the cellular location of mmB-CFA synthesis differed from that of palmitate, we traced adipocytes with H]glucose. Deuterium labeling on the third carbon of glucose specifically labels cytosolic NADPH via the oxidative pentose phosphate pathway but is lost in glycolysis and does not label citrate, acetyl-CoA or mitochondrial NADPH (Fig. 1f) 
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. If a significant portion of mmBCFAs were synthesized within mitochondria, decreased 2 H enrichment relative to palmitate would be expected. We found that cytosolic NADPH effectively labeled both mmBCFAs and palmitate, suggesting that these FAs were primarily synthesized in the cytosol by FASN (Fig. 1g) , albeit at slower rates than palmitate ( Supplementary Fig. 1e,f) . Next, we generated pooled cultures of 3T3L1 adipocytes with CRISPR-Cas9-mediated FASN knockout (KO) before differentiation ( Supplementary Fig. 2a-b) . Though the abundance of all FAs decreased, mmBCFAs were undetectable in all FASN KO cells and abundant in sgNT cells (Fig. 1h) . However, differentiation was significantly impaired (Supplementary Fig. 2c ). To further confirm that FASN deficiency rather than impaired differentiation and lack of substrate decreased BCFA synthesis, we supplemented cultures with the short branched-chain FAs isobutyrate, isovalerate, 2-methyl-butyrate, and propionate. Addition of these substrates increased the abundance of mmBCFA and OCFA in a dose-dependent manner ( Fig. 1i; Supplementary Fig. 1d-f ). Whereas iso-C16:0 levels significantly increased in control adipocytes and in nondifferentiated pre-adipocytes upon addition of isobutyrate, iso-C16:0 levels were still undetectable in FASN KO cells ( Supplementary Fig. 2g ), indicating that lack of FASN rather than impaired differentiation was the primary reason for the absence of BCFA synthesis. Furthermore, treatment with the FASN inhibitor TVB3166 significantly decreased the synthesis of both iso-C16:0 and palmitate ( Supplementary Fig. 2h ). Although the mitochondrial FAS II system may also contribute to mmBCFA synthesis, our results demonstrate that cytosolic de novo lipogenesis via FASN promiscuity is the primary driver of mmBCFA production in adipocytes 22 .
BCAA catabolic intermediates drive mmBCFA synthesis. The minor impact of B12 availability on iso-C16:0 and iso-C17:0 suggests that these FAs are not synthesized via elongation of methylmalonyl-CoA. Administration of radioisotopes in rats has indicated that BCAAs are precursors for mmBCFAs in skin 23 . In addition, provision of isovaleryl-CoA, isobutyryl-CoA or 2-methylbutyrylCoA to enzyme extracts from rat epididymal tissue results in the production of mmBCFAs 22 . To confirm that this pathway architecture exists within intact adipocytes, we cultured adipocytes with uniformly 13 C-labeled BCAAs and quantified labeling via GC-MS. This resulted in distinct labeling patterns for each of their respective mmBCFAs (Fig. 2a-d) . Carbon from [U- 13 C 5 ]valine was only incorporated into iso-C16:0 and resulted in a prominent M + 4 peak in the isotopologue distribution, indicating that the valine catabolic intermediate isobutyryl-CoA was used to synthesize iso-C16:0 (Fig. 2a,b) . Similarly, iso-C17:0 from [U- 13 C 6 ]leucine and anteiso-C17:0 from [U- 13 C 6 ]isoleucine exhibited distinct M + 5 shifts, indicating that isovaleryl-CoA and 2-methylbutyryl-CoA were used for mmBCFA synthesis (Fig. 2a,c,d ). Notably, we detected no FA isotopologues of M + 8 or M + 10, demonstrating that only a single incorporation of these branched intermediates into the acyl chain was occurring in these cells. This result, combined with the observation that only mmBCFAs with a branch at the penultimate or antepenultimate end were detected, supports a mechanism whereby FASN is promiscuous and can use short acyl-CoAs to initiate synthesis of long-chain FAs.
Multiple acyl-CoA dehydrogenases (ACAD) are annotated to carry out the dehydrogenations of isovaleryl-CoA, 2-methylbutyryl-CoA, and isobutyryl-CoA. To evaluate the specific roles of these enzymes in BCAA catabolism and mmBCFA synthesis, we targeted various ACAD enzymes via shRNA-mediated knockdown and quantified FA abundances after adipocyte differentiation ( Supplementary  Fig. 3a-c) . Knockdown of ACAD8, IVD and ACADSB specifically and significantly increased levels of iso-C16:0, iso-C17:0 and anteiso-C17:0, respectively ( Fig. 2e-g; Supplementary Fig.  3d-f) . Targeting of ACADM and ACADS did not impact mmB-CFA levels appreciably. Each mmBCFA accumulated differently, with valine-derived iso-C16:0 having the highest abundance ( Fig. 1a; Supplementary Fig. 3d ), inversely consistent with the relative expression of each dehydrogenase (Fig. 2h) . These findings indicate that ACAD enzyme expression influences the metabolic fate of BCAAs and mmBCFA production. mmBCFAs are incorporated into distinct lipid species. The above data are representative of total hydrolyzed FA pools in the cell. To further characterize the metabolic fate of mmBCFAs, we next sought to determine whether mmBCFAs were incorporated into distinct lipid species. Distinguishing lipids containing different acyl chain isomers such as iso-C16:0 and C16:0 (palmitate) with liquid chromatography is challenging because of the decreased isomer resolution compared to gas chromatography, and there have been limited reports of mmBCFAs in specific, intact lipids 11, 24 . To circumvent this issue we used [U- Supplementary Fig. 4d,e) . The highest percent of total enrichments was observed in species containing alkyl chains, suggesting that iso-C16:0 may be selectively incorporated into ether lipids. Notably, some BCFAs (for example, phytanic acid) must be trafficked to the peroxisome for α -oxidation, and peroxisomes are the site for ether lipid synthesis because of the presence of alkyl DHAP synthase and DHAPAT. As such, mmBCFAs may be similarly directed to the peroxisome, leading to the observed high enrichment in abundant alkyl-lipids. Other significantly enriched lipids included sphingomyelin, phosphatidylserine, phosphatidylcholine, phosphatidylinositol and triacylglycerols (TAGs). In fact, induction of lipolysis via isoproterenol treatment resulted in significant mmBCFA secretion into culture medium, indicating that these FAs are present in lipid droplets ( Supplementary Fig. 4f ).
mmBCFAs are de novo synthesized in vivo. To determine whether mmBCFA synthesis occurs in vivo, we quantified the abundances of each mmBCFA across various tissues in male and female C57BL/6 J mice. Consistent with our observation of mmBCFA synthesis in adipocytes, white and brown adipose tissues (WAT and BAT) exhibited the highest abundances of all mmBCFAs, including iso-C18:0, an elongated derivative of iso-C16:0 that was not detectable in 3T3L1 cultures ( Fig. 3a, b; Supplementary Fig. 5a ,b). Liver and brain exhibited the lowest abundances of mmBCFAs, suggesting that FA composition is regulated in a tissue-specific manner. In addition, iso-C17:0 abundance differed between males and females, potentially because of hormonal effects on BCAA catabolism 25 . With the exception of anteiso-C17:0, total mmBCFAs (free and lipid bound) were present in plasma at micromolar concentrations ( Supplementary Fig. 5c ), and their abundances increased 2-3 fold in plasma upon prolonged fasting ( Fig. 3c ; Supplementary  Fig. 5d ). Although these measurements are of total rather than free FAs, these data suggest that iso-BCFAs are released from adipose tissue via lipolysis along with other FAs.
As microbial metabolism is a source of both long and short BCFAs 26, 27 ( Supplementary Fig. 6a ), the gut microbiome could be a significant source of mmBCFAs in animals. In addition, mmBCFAs are present in chow ( Supplementary Fig. 6b ), and thus diet will also contribute to mmBCFA levels in vivo. To determine the relative contribution of de novo synthesis versus diet and the impact of microbiota on mmBCFA levels, we administered 2 H 2 O to germ-free and specific pathogen-free (SPF) control mice for 8 d and measured enrichment of FAs in lipogenic tissues 28 ( Fig. 3d) . A significant fraction of the mmBCFAs present were newly synthesized in both germ free and SPF mice ( Fig. 3e, f; Supplementary Fig. 6c,d ). Valine-derived iso-C16:0 was the most abundantly synthesized mmBCFA ( Fig. 3g, h ; Supplementary  Fig. 6e,f) , and the fraction of newly synthesized iso-C16:0 was similar to that for palmitate (C16:0) in eWAT, iWAT and BAT ( Fig. 3e, f ; Supplementary Fig. 6c ). Overall, these data indicate that de novo synthesis is a significant source of mmBCFAs in vivo, and their production can occur in the absence of microbiota. However, both levels ( Supplementary Fig. 6g-j) and synthesis of mmBCFAs and other FAs differed significantly in the adipose tissues of germ-free and SPF mice, indicating that microbiota impacts lipogenesis and FA diversity. To confirm that de novo synthesis of mmBCFAs occurs in humans, we analyzed plasma from NAFLD patients who were administered Table 2 and Supplementary  Fig. 6k,l) . Analysis of deuterium enrichment of FAs demonstrated that both OCFAs and mmBCFAs were synthesized de novo in humans (Fig. 3i) . Plasma mmBCFAs were present in the range of 1-20 μ M in these patients ( Supplementary Fig. 6m ), comparable to those of other long and very long chain FAs such as C20:0 and C24:0 (ref. 29 ).
BCAA flux to mmBCFAs is decreased by diet-induced obesity.
Clinical studies have indicated that BCAA metabolism is dysregulated in the context of metabolic syndrome, as plasma BCAAs and some catabolites are elevated in insulin-resistant patients 1, 2 . Additionally, BCAA catabolic enzyme expression is decreased in rodents fed a high-fat diet (HFD) 17 . Conversely, plasma mmBCFAs are decreased in morbidly obese patients 15 . To determine whether mmBCFA levels change in mouse models of obesity, we quantified total FAs in plasma and WAT of mice fed a HFD or low-fat diet (LFD) for 15 weeks. Although intake of all FAs (including mmBCFAs) was increased in the HFD cohort ( Supplementary  Fig. 7a ), iso-BCFA abundances were significantly lower ( Fig. 4a,b ; Supplementary Fig. 7b-c) . In terms of fold changes, valine-derived iso-C16:0 and iso-C18:0 were the most differentially abundant FAs in these tissues. Relative abundances of straight-chain FAs increased or remained unchanged, with the exceptions of C16:1 (palmitoleate) and C15:0 (Fig. 4a) . Similar results were observed in ob/ob mice, in which mmBCFAs were significantly decreased in iWAT relative to control mice ( Supplementary Fig. 7d ). Notably, anteiso-C17:0 levels increase in the plasma of HFD mice (Fig. 4b) . Given that synthesis of anteiso-C17:0 was nearly undetectable in 2 H 2 O traced mice (Fig. 3g,h ), this FA is primarily diet derived and synthesis from isoleucine is not significant in vivo. These results demonstrate that individual FAs change distinctly with the onset of obesity depending on their origin and metabolism.
To directly investigate altered BCAA catabolism in the context of metabolic syndrome, we fed C57BL/6 J mice a HFD or LFD for 12 weeks and then identical diets formulated with 25% enriched [U- were elevated ( Supplementary Fig. 8b ), plasma BCAA levels were unchanged ( Supplementary Fig. 8c ), consistent with recent studies in C57BL/6J mice 30 , and we observed no differences in enrichment of plasma leucine and valine ( Supplementary Fig. 8d ). However, significant differences were present within tissues ( Supplementary  Fig. 8e ,f). We detected significant 13 C enrichment of citrate and palmitate in all tissues measured (Fig. 4c,d ), indicating that leucine catabolism is a significant source of acetyl-CoA in vivo. In the HFD cohort, 13 C enrichment and molar abundance in citrate and palmitate, respectively, were significantly decreased in all tissues, with BAT being the most impacted, demonstrating that diet-induced obesity decreases BCAA catabolism (Fig. 4c,d ). The leucine and valine-derived mmBCFAs had characteristic mass shifts of M + 4 and M + 5, indicating that these FAs were synthesized de novo from BCAAs in vivo ( Fig. 4e; Supplementary Fig. 8g,h ). Importantly, molar enrichment of iso-BCFAs from valine and leucine were decreased in total FA pools from almost all tissues analyzed ( Fig. 4f ; Supplementary Fig. 8i ,j). The highest abundances of newly synthesized, long-chain iso-BCFAs were present in BAT, although crosstissue transport is likely significant given the high FA enrichments detected in muscle and heart. Collectively, these data indicate that diet-induced obesity significantly decreases BCAA catabolic flux, and a downstream result of this regulation is lower mmBCFA synthesis and abundance throughout the body.
In contrast to mmBCFAs, we did not detect a pronounced M + 3 shift in OCFAs ( Supplementary Fig. 8k ), consistent with the abundance of other propionate sources in animals (for example, gut microbes, OCFA oxidation, and cholesterol breakdown) or their production via α -oxidation 31 . Although valine is a source of propionate in cultured adipocytes, this pathway is not a major source of OCFAs in vivo under normal physiological conditions 6, 7 . However, we did note some incorporation of BCAA-derived carbon into , eWAT (n = 7), BAT (n = 7), heart (n = 5) and HFD iWAT (n = 4), BAT (n = 7), heart (n = 4). d, 13 C molar enrichment of C16:0. N = 8 for all comparisons except LFD eWAT (n = 7), heart (n = 5) and HFD iWAT (n = 7). e, Isotopologue distribution of iso-C16:0 from [U- 13 C 5 ]valine (HFD, n = 8; LFD, n = 8). f, 13 C molar enrichment of iso-C16:0. N = 8 for all comparisons except HFD iWAT (n = 7), liver (n = 5) and brain (n = 6). Two-tailed Student's t-test was performed for each comparison in this figure with no adjustment for multiple comparisons. Data are presented as means ± s.e.m. with dot plot overlaid (a-d, f) or box (25th to 75th percentile with median line) and whiskers (min. to max. values) (e).
OCFAs via acetyl-CoA ( Supplementary Fig. 8l,m) , indicating that OCFAs are also de novo synthesized to some extent in vivo.
Adipose tissue mmBCFA synthesis is facilitated by CrAT. The above results demonstrate that BCAA catabolic flux contributes significantly to de novo lipogenesis in vivo, and mmBCFAs are abundant products of this pathway. The large (~10-fold) differences in abundance within liver and adipose tissues (Fig. 3a,b) suggest that mmBCFA synthesis is regulated distinctly in these tissues. To assess the impact of diet on tissue-specific mmBCFA synthesis and enable a comparison to synthesis of other FAs, we administered 2 H 2 O to HFD and LFD mice and measured enrichment in lipogenic tissues. Newly synthesized iso-C16:0 and iso-C18:0 were decreased in livers of HFD mice more than any other FA in terms of fold-change (Fig. 5a ). In contrast, straight-chain and monounsaturated FA synthesis in the liver was increased or remained the same ( Fig. 5a; Supplementary Fig. 9a ). Within adipose tissues, HFD feeding decreased lipogenesis of all FAs, indicating that pathway activity is generally suppressed ( Fig. 5b; Supplementary  Fig. 9b-d) as previously observed 32, 33 . We next estimated FA synthesis and turnover occurring in each tissue on the basis of the molar abundance of each FA, fraction synthesized, and length of time the tracer was administered. mmBCFA turnover was highest in white and brown adipose tissues but substantially lower in liver ( Fig. 5c; Supplementary Fig. 9e-g ). Though brown adipose tissue exhibited the highest synthesis and turnover for all FAs, these measurements are likely a lower estimate because they do not account for β -oxidation and futile FA cycling, which are likely quite high in brown adipocytes 34 . HFD suppressed the synthesis of all FAs in adipose tissues but increased palmitate synthesis and turnover in liver (Fig. 5d) . These results suggest that subcutaneous and brown adipocytes exhibit a high capacity for mmBCFA synthesis when lipogenesis is active in these depots. Indeed, mmBCFA synthesis in brown adipose tissue is significantly increased in cold-exposed mice (Fig. 5e) , similar to the increased de novo lipogenesis of other FAs 34 . Liver exhibited relatively low abundances of newly synthesized mmBCFAs compared to other lipogenic tissues, and these levels decreased further in response to HFD, which contrasts to the changes observed for other FAs in the liver. Importantly, this tracing method does not account for lipid efflux and intertissue FA transport, and thus likely underestimates absolute FA synthesis in liver. Nevertheless, our collective data on abundance and synthesis of all FAs strongly indicate that mmBCFAs are synthesized in adipose tissues but not liver.
BCAA catabolism and lipogenesis are highly active in liver, so we next attempted to address why mmBCFA synthesis is specific to adipose tissues. mmBCFA synthesis requires BCAA catabolic intermediates to be exported from the mitochondria into the cytosol for elongation by FASN. Prior studies have demonstrated that CrAT, but not carnitine palmitoyltransferase 2 (CPT2), exhibits , or acclimatized to severe cold (6 °C) over 1 month (n = 6 per group). f, Crat expression relative to liver in tissues from male C57BL/6J mice (n = 4). g, Relative abundance of total FAs in pooled CRISPR-Cas9 Crat KO 3T3L1 adipocytes. Representative data from three cell replicates. Three independent infections have been carried out with the same result. Data is presented as box (25th to 75th percentile with median line) and whiskers (min. to max. values) (a-f) or means ± s.e.m. with dot plots overlaid (g). Two-tailed Student's t-test was performed for each comparison in this figure with no adjustment for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001. enzyme activity toward BCAA-derived, short branched-chain CoAs 35 . Therefore, we hypothesized that CrAT facilitates mmB-CFA synthesis in adipose tissues. Crat mRNA is expressed at low levels in liver but exhibits high expression in muscle and adipose tissues (Fig. 5f) . Additionally, quantitative proteomics indicates that CrAT is expressed at higher levels in white and brown adipose tissue compared to liver and brain ( Supplementary Fig. 10a ) 36 . Thus, tissue-specific CrAT expression may be a driver of the observed differences in mmBCFA abundance and synthesis between liver, brain, and adipose tissues.
To more directly determine how CrAT influences mmBCFA synthesis, we generated CrAT KO 3T3L1 cells using CRISPR-Cas9 (Supplementary Fig. 10b ). In contrast to the results with FASN KO, CrAT KO did not appreciably impact adipogenesis ( Supplementary  Fig. 10c,d ). However, CrAT KO adipocytes had significantly decreased levels of both mmBCFAs and OCFAs (Fig. 5g) , with minimal differences in the levels of other FAs (Supplementary Fig. 10e ). These data indicate that CrAT is an important component of the mmBCFA synthesis pathway, facilitating cytosolic export of precursor acyl-CoAs (Supplementary Fig. 10f ). Differential expression of this enzyme in liver versus BAT and WAT likely contributes to the tissue specificity of mmBCFA synthesis and abundance.
Hypoxia suppresses BCAA catabolism and mmBCFA synthesis. Our data indicate that mmBCFAs are predominantly synthesized in adipose depots, and they decrease in the context of diet-induced obesity and increase in plasma during prolonged fasting. Given the adipose origin of mmBCFAs, we sought to determine the physiological factors that drive decreased BCAA catabolism and mmBCFA synthesis in obesity in vivo. Hypoxia has been proposed as a key contributory factor to adipose tissue dysfunction in obesity 37 , and increasing adipose vascularization improves insulin sensitivity 38 . To test the impact of hypoxia on BCAA metabolism in adipocytes, we incubated differentiated 3T3L1 adipocytes in 1% oxygen for 24 h before switching to hypoxia-equilibrated media containing uniformly 13 C-labeled amino acids or glucose for an additional 24 h. Intracellular BCAAs and α -ketoisocaproate accumulated significantly in hypoxic cultures along with lactate and 2-hydroxyglutarate (Fig. 6a) . Media analysis demonstrated that glycolytic flux increased along with net glutamine consumption, whereas BCAA uptake decreased approximately 3-4 fold (Fig. 6b) . Consistent with these flux changes, TCA intermediate enrichment from [U- 13 C]BCAAs was decreased under hypoxia (Fig. 6c) . Isotopomer spectral analysis (ISA) demonstrated that the relative contribution of leucine to lipogenic acetyl-CoA decreased significantly, whereas the contribution of glutamine to FAs increased (Fig. 6d) . Notably, hypoxia generally decreased the synthesis of FAs, including OCFAs and mmBCFAs (Fig. 6e) . Collectively, these data indicate that hypoxia strongly decreases BCAA catabolism. These results were recapitulated in primary cells derived from various tissues, including murine brown adipocytes, human skeletal myotubes, and white adipocytes ( Supplementary Fig. 11a ).
Bckdha and Bcat2 mRNA and protein product were decreased under hypoxia in 3T3L1 adipocytes ( Supplementary Fig. 11b-d) . Additionally, we observed that adipose tissue oxygen tension and arterial blood flow were specifically decreased in HFD mice along with BCKDHA protein levels ( Supplementary Fig. 11e-g ), corroborating previous findings in obese adipose tissue 17, 39 . Overall, these data indicate that adipose tissue in obese animals exhibits lower oxygen tension, which may contribute to the observed decreases in BCAA catabolism and the BCKDHA levels we observed in adipose tissue from HFD mice. In turn, decreased flux through this pathway decreases local and circulating iso-mmBCFA levels in obesity.
Discussion
Here, using in vitro and in vivo metabolic tracing, we define a cross-tissue metabolic pathway in which BCAA catabolic flux and the promiscuity of FASN and CrAT within brown and white adipose tissues support mmBCFA synthesis. Additionally, we demonstrate that mmBCFA turnover is suppressed by HFD and obesity-induced adipose hypoxia. Collectively, these results demonstrate that mmBCFAs are endogenous FAs produced by adipocytes that link mitochondrial BCAA catabolism, lipogenesis, and diet to metabolic disease.
To date, the primary metabolic role of BCAA catabolism has been attributed to its importance as a nitrogen donor 40 , to the production of HIBA to modulate FA uptake 41 , and to the generation of branched acyl intermediates that can modulate enzyme function via post-translational modifications 42 . Our data add to this knowledge, linking BCAA catabolism to modulation of FA diversity via enzyme promiscuity. Interestingly, mmBCFAs are synthesized and present at low levels in liver despite the high abundance of BCKDH and rate of lipogenesis 43, 44 . We provide evidence that this difference is driven by differential expression of Crat, encoding an enzyme that has predominantly been studied in muscle, where it is thought to mitigate fatigue by facilitating acetyl-CoA consumption during exercise and preventing acetyl-CoA accumulation during rest 45 , thus decreasing macronutrient-induced lysine acetylation of mitochondrial proteins 46 . However, its relevance in brown and white adipose tissues has not been explored, despite the high level of expression observed in brown adipose tissue 36 . Given recent evidence that branched acyllysine modifications also alter mitochondrial enzyme function 42 , it is possible that diversion of branched CoA intermediates to longchain FAs via CrAT is beneficial for maintaining healthy mitochondrial function.
We also highlight an underappreciated aspect of de novo lipogenesis, whereby the de novo FA composition reflects the balance of acyl-CoAs within the body. Thus, FASN promiscuity integrates changes in amino acid metabolism and short-chain FAs into the lipidome. Therefore, alterations in SCFA and acyl-CoA abundance driven by the gut microbiome, diet, or inborn errors of metabolism can influence FA diversity and must be considered when studying the pathophysiology of associated diseases. Indeed, elevated levels of mmBCFAs have been detected in the brains of patients with defects in cobalamin metabolism 18 . Supraphysiological levels of mmBCFAs could impact neuronal function and play a role in the neurological defects that occur in patients with certain organic acidemias or B12 deficiency. This work also highlights the limited resolution of most lipidomics platforms for resolving mmBCFA-containing lipids. We found that mmBCFAs are incorporated into diverse lipid species by cultured adipocytes, including ether lipids, TAGs, and phospholipids.
However, more extensive and focused approaches are needed to fully characterize their fates within different tissues. Using 13 C-labeled leucine and valine chow, we observed that HFD feeding suppressed BCAA catabolism, resulting in decreased mmBCFA synthesis. This result is consistent with transcriptional and other flux-based measurements that indicate downregulation of this pathway in mouse models of obesity and in diabetic patients 17, 47 . In fact, mmBCFAs correlate negatively with metabolic disease biomarkers such as C-reactive protein and insulin resistance in patients 15, 16 . This contrasts with levels of BCAAs and their downstream catabolic intermediates, which increase in the plasma of insulin-resistant patients 1, 41 . However, BCAA levels did not increase in our model of diet-induced obesity, and thus mmBCFA levels did not correlate with BCAA levels as might be expected. This is presumably due to the adipose-specific origin of these FAs, as BCAAs are widely catabolized in energetically demanding tissues such as muscle, liver, heart and brain, which are not significant sources of mmBCFAs. Furthermore, turnover and abundance of BCAA is much greater than that of mmBCFA. Therefore, although mmBCFA synthesis is impacted by BCAA catabolic flux, differential mmBCFA production is unlikely to be a primary driver of BCAA accumulation in T2D patients. Nevertheless, mmBCFAs may be a strong biomarker of adipose tissue lipogenesis and BCAA catabolism, and, in contrast to circulating BCAA levels, are not overtly influenced by changes in protein turnover and muscle insulin resistance.
The functional consequences of decreased mmBCFA levels are unknown. Despite their abundance in tissues and presence at micromolar levels in plasma, mmBCFAs have been studied minimally in the context of mammalian biology. mmBCFA-containing lipids play critical roles in the postembryonic growth, neuronal development and the foraging behavior of C. elegans 11, 48 . In prokaryotes BCFAs influence membrane fluidity, and their abundances change in response to certain stresses 10, 26 . In mammalian biology, previous studies have suggested they influence colon epithelial cell inflammation 49 and protect against necrotizing enterocolitis 50 . Our insights into the metabolic origins and fates of mmBCFAs suggest other potential functions. As mmBCFAs are primarily synthesized in adipose tissue, incorporated into TAGs, and increase in plasma during fasting, these lipids may be involved in nutrient sensing and signal to other tissues in the body. However, given the relatively low abundance of mmBCFAs, these FAs are unlikely to contribute significantly to energy storage or substrate oxidation and are more likely to play a role in signaling or membrane structure. Ultimately, understanding the factors that regulate mmBCFA physiology is an essential step in elucidating their function and contribution to the biological importance of the BCAA catabolic pathway.
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Methods
Materials and reagents. Media and sera were purchased from Life Technologies. Glucose and amino acid isotope tracers were purchased from Cambridge Isotopes Inc. Fatty acid standards were purchased from Larodan. All other reagents were purchased form Sigma-Aldrich unless otherwise noted.
Cell culture. 3T3L1 pre-adipocytes were purchased from the American Type Culture Collection and cultured in high glucose Dulbecco's modified Eagle medium (DMEM; Life Technologies) supplemented with 10% bovine calf serum (BCS) below 70% confluence. For differentiation, cells were allowed to reach confluence (day − 2), and 2 d post confluence (day 0) differentiation was induced with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 0.25 µ M dexamethasone, and 1 µ g/ml insulin in DMEM containing 10% FBS. Media was changed on day 2 to DMEM + 10% FBS with 1 µ g/ml insulin. On day 4 and thereafter, DMEM + 10% FBS was used. Cobalamin (500 nM) was supplemented to cultures when noted. Isotope tracing was carried out 7 d post induction of differentiation unless otherwise noted. Cells were incubated in custom DMEM in which the metabolite specified was replaced with the 13 C-or 2 H-labeled version for 24 h unless otherwise specified. For short-chain fatty acid addition experiments, individual short-chain fatty acids were added to the media at the indicated concentration for 24 h, after which total fatty acids were extracted as described below. Fatty acids were then calculated as percent total fatty acids and normalized to control conditions. For LC-MS analysis of [U- BAT depots were isolated from the interscapular area of neonate mice as previously described 51 . Once cells reached confluency, differentiation was induced by addition of DMEM containing 10% FBS, 20 nM insulin, 1 nM triiodothyronine, 0.5 mM 3-isobutyl-1-methylxanthine, 2 μ g/mL dexamethasone, and 0.25 mM indomethacin for 2 d and then switched to differentiation media containing 20 nM insulin, and 1 nM triiodothyronine for 5-6 d. Isotope tracing was carried out 7 d post induction of differentiation.
Primary human white pre-adipocytes and muscle satellite cells were isolated, propagated and differentiated and then cultured for 24 h in tracer media as previously described 7, 52 . Weight stable obese subjects undergoing elective laparoscopic gastric bypass via Roux-en-Y for the treatment of obesity were recruited for the study to provide material for pre-adipocyte isolation. Both human skeletal muscle biopsies and material for pre-adipocyte isolation were obtained with approval from the University of California San Diego's Committee on Human Investigation and VA San Diego Medical Center's Institutional Review Board. All donors provided informed written consent after listening to an explanation of the protocol, and the study complied with all relevant regulations.
All hypoxia experiments were carried out in a Coy hypoxia chamber, which allows media changes under hypoxic conditions. ND-646 (1,4- Table 3 ) and a nontargeting control construct were purchased from Sigma-Aldrich and packaged in HEK293FT cells using the transfection agent Fugene 6 and required packaging plasmids VSV-G, gag/pol, and rev. HEK293FT medium containing lentiviral constructs was collected 2 d later and filtered (0.45 μ m). Polybrene was added to a final concentration of 6 μ g/ml. 3T3L1 pre-adipocytes were infected with 0.5 ml of virus-containing medium in a 6-well plate for 4 h before addition of 2 ml of virus-free medium. After 24 h of recovery, transduced cells were selected with 3 μ g/ml puromycin. Cells were then plated to 12-well plates for differentiation as described above. Puromycin was removed from the medium beginning on day 0 of differentiation. Table 4 ) were cloned into the lentiCRISPRv2 plasmid (Addgene plasmid # 52961). For lentivirus production, 2-2.5 million HEK293FT cells were placed in 10-cm tissue culture plates in 10 ml of DMEM (containing 1% penicillin/streptomycin, 10% FBS). 24 h later, transfection was performed using Lipofectamine 3000 (Invitrogen) with 1.3 μ g VSV.G/PMD2.G, 5.3 μ g of lenti-gag/pol/PCMVR8.2 and 4 μ g of lentiviral vector. Lentivirus-containing supernatants were harvested 48 and 72 h later and concentrated using Amicon Ultra-15 centrifugal filters, 100,000 NMWL (Millipore) following the manufacturer's protocol. 3T3-L1 pre-adipocytes were infected with 10 μ L of virus in 1 ml of medium containing 7.5 μ g of polybrene in a 6-well plate for 4 h before addition of an extra 1 ml of virus-free medium. After 24 h of recovery, transduced cells were selected with 3 μ g/mL puromycin. Cells were then plated to 12-well plates for differentiation as described above. Puromycin was removed from the medium beginning on day 0 of differentiation.
Pooled CRISPR-Cas9 KO of Crat and Fasn in 3T3L1 adipocytes. Fasn, NT and CrAT target sequences (Supplementary
RNA isolation and quantitative RT-PCR.
Total RNA was purified from cultured cells using Trizol Reagent (Life Technologies) per the manufacturer's instructions. First-strand cDNA was synthesized from 1 μ g of total RNA using iScript Reverse Transcription Supermix for RT-PCR (Bio-Rad Laboratories) according to the manufacturer's instructions. Individual 10 μ l SYBR Green real-time PCR reactions consisted of 2 μ l of diluted cDNA, 5 μ l of SYBR Green Supermix (Bio-Rad), and 1 μ l of each 5 μ M forward and reverse primers. For standardization of quantification, 18 S was amplified simultaneously. The PCR was carried out on 96-well plates on a CFX Connect Real time System (Bio-Rad) using a three-stage program provided by the manufacturer: 95 °C for 3 min, 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Gene-specific primers used are listed in Supplementary Table 5 . PCR data for intergene comparison were corrected for primer efficiency.
Western blots. 3T3L1 adipocytes or 100-150 mg of ground eWAT were lysed in ice-cold RIPA buffer with 1 × protease inhibitor (Sigma-Aldrich). 30 μ g total protein was separated on a 12% SDS-PAGE gel for BCKDH blots or 20 μ g of total protein was separated on a 4-20% SDS-PAGE gel (mini-protean TGX gels, BioRad) for CrAT and FASN blots. The proteins were transferred to a nitrocellulose membrane and immunoblotted with anti-Bckdha (Novus Biologicals NBP1-79616) (1:1,000 dilution), anti-β -actin (Cell Signaling 4970 S) (1:5,000), anti-GAPDH (Cell Signaling 5174 S), anti-CrAT (Novus NBP2-15999), anti-FASN (Proteintech 10624-2-AP). Specific signal was detected with horseradish peroxidase-conjugated secondary antibody goat anti-rabbit (1:2,500-1:10,000) using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and developed using Blue Devil Autoradiography film (Genesee Scientific) or Bio-Rad Chemidoc XRS + .
Animal studies. Animal handling and care followed the NIH Guide for Care and Use of Laboratory Animals. The experimental protocols were approved by either the UCSD, Salk or UMMS Institutional Animal Care and Use Committee. C57BL/6 J and ob/ob(B6.Cg-Lepob/J) were obtained from Jackson Laboratories.
Mouse fasting study. Food was removed from cages containing 12-week-old male or female C57BL/6 J mice (3-4 mice per cage) at 7:00 a.m. Blood was collected via tail bleed at baseline, 2, 6 12 and 24 h post removal of food. Mice remained in their original cage with original bedding (nonsynthetic shavings) for the duration of the experiment.
H O administration to animals.
For the comparison of germ free and specific pathogen free mice, male Swiss Webster mice were bred and maintained in sterile semi-flexible isolators and screened for bacterial, viral, and fungal contamination. Age-matched male specific pathogen-free mice were used for comparison and obtained from Charles River at 5 weeks of age. Mice were maintained under a 12 h light/dark cycle and given a standard chow diet ad libitum. At 6 weeks of age, mice were subcutaneously injected with 0.035 ml/g body weight 0.9% NaCl 2 H 2 O, and drinking water was replaced with 8% 2 H 2 O enriched water. 8 d later, mice were fasted for 6 h (9 a.m. to 3 p.m.) and tissues collected and snap frozen in liquid N 2 .
For the high-fat study, 5-week-old C57BL/6 J mice were obtained from Jackson Laboratories and ad lib fed a 45% high-fat diet (D12451) or a 10% low-fat diet (D12450K) for 15 weeks from 6 weeks of age. Diets were obtained from Research Diets, Inc. 7-21 d before termination, mice were injected intraperitoneally with 0.035 ml/g body weight 0.9% NaCl 2 H 2 O, and drinking water was replaced with 8% 2 H 2 O-enriched water. Mice were fasted for 6 h before plasma, and tissue collection and samples were immediately snap frozen in liquid N 2 .
Thermovariation experiments were carried out as previously described 34 . Briefly, 10-week-old C57BL/6 J mice were simultaneously housed in two rodent incubators (RIT33SD, Powers Scientific) within the Animal Medicine facilities of the UMMS for 4 weeks. One of them had the temperature adjusted to 30 °C (thermoneutrality group). Another incubator had its temperature decreased by four degrees weekly until reaching 6 °C, and the mice stayed at this temperature for a week (severe cold group). Room-temperature group mice were in a clean room set at 22 °C co-housed in the same facility as the mice in rodent incubators. Mouse cages were changed weekly using components pre-adjusted to temperature. Three days before termination, mice were intraperitoneally injected with 0.035 ml/g body weight 0.9% NaCl Tissue pO 2 and organ blood flow in HFD/LFD mice. To determine the impact of obesity on tissue pO 2 , blood flow and BCKDHA levels in eWAT, 5-week-old C57BL/6 J mice were obtained from Jackson Laboratories and ad lib fed a 60% kcal high fat diet (D12492) or a 10% kcal fat diet (D12450K) from research diets for 8 weeks from 6 weeks of age.
Electrodes for oxygen measurements. The oxygen partial pressure was measured using carbon fiber electrodes (Carbostar-1, Kation Scientific; Minneapolis, MN) in which the tip of the electrode was coated with 5% Nafion (Sigma; St. Louis, MO) to increase oxygen specificity. The process consisted of three individual Nafion coats. The microelectrodes were polarized at − 0.8 V relative to a silver-silver chloride reference electrode (Cypress Systems; Lawrence, KS). Oxygen measurements were performed using the two electrodes system (working and reference electrode), and the current generated was measured with a potentiostat and electrometer (Keithley model 610 C; Cleveland, OH). The microelectrodes were calibrated at 37 °C with 0, 5, 10 and 21% oxygen gases (Airgas; Los Angeles, CA). Tissues were superfused (0.1 ml/min) with physiological Krebs salt solution, and the tissue was maintained at 35-37 °C by the heated Krebs solution. The solution was spread on the tissue as a thin film, drained into a platter, and drawn off by suction. The solution was equilibrated with 95% N 2 and 5% CO 2 , which maintained the superfusate at a pH of 7.4 and minimized O 2 delivery to the tissue from the atmosphere. Oxygen measurements were made by penetrating the tissue with the microelectrode tip. The reference electrode was placed in the bath, and the microelectrode was placed in a shielded holder and advanced toward the measurement site with a micromanipulator. A long-working distance X10 Leitz objective was used to direct the electrode to the measurement site. Before measurements, the electrode tip was immersed in the supernatant suffusion solution and the current was registered. The supernatant suffusion solution was set as 0 mm Hg reference point. Upon introduction into the tissue, the microelectrodes responded with a time constant that is estimated to be of the order of 10 s. A stable reading is obtained within 30 s, and upon reaching the current plateau value, the electrode is extracted from the tissue and the tip maintained within the suffusing saline solution.
Organ blood flow distribution. The fluorescent-labeled microsphere (FLM) method was used to determine organ blood flow. Briefly, fluorescent microspheres (Molecular Probes, Eugene, OR), 15 μ m in diameter with a single color (green, yellow, red or scarlet) were suspended in saline and injected over a short 10 s period (100 μ L) at the time point of interest. At the end of the protocol, animals were euthanized with a lethal dose of sodium pentobarbital, and eight vital tissues were harvested. The tissues were digested in 1 N KOH in separate containers for 24 h and then filtered. Fluorescent dye extraction was accomplished using Cellosolve (Fisher Scientific Co., Pittsburg, PA), and the number of FLMs was quantified as a function of the florescent signal at each specific FluoSphere wavelength (LS50B, PerkinElmer Corp., Norwalk, CT) 53 .
NAFL/NASH patient sample collection. Sixteen subjects undergoing diagnostic liver biopsy for suspected NAFLD were recruited by the NAFLD Research Center at the University of California, San Diego. Subjects were carefully screened and excluded for liver diseases other than NAFLD and secondary causes of hepatic steatosis 54 . Subjects drank 50 ml of 70% 2 H 2 O three times per day for 4 d, followed by twice a day until the date of liver biopsy, for a total period of 3-5 weeks. Plasma was collected weekly from the start of heavy water labeling until the time of biopsy. All procedures used in this study were approved by the University of California, San Diego Human Research Protections Program. Subjects provided written informed consent, and Declaration of Helsinki protocols were followed.
GC-MS analysis of fatty acids and polar metabolites. For cell culture, polar metabolites and fatty acids were extracted using methanol/water/chloroform and analyzed as previously described 7 . For tissue and plasma, metabolites and total fatty acids were extracted from tissues and plasma using a Folch-based methanol/ chloroform/saline extraction at a ratio of 1:2:1 with inclusion of [ 2 H 31 ]palmitate and norvaline as lipid and polar internal standards, respectively. Briefly, 250 μ l MeOH, 500 μ l CHCL3, 250 μ l saline and fatty acid isotope internal standards were added to weighed preground tissue. This was vortexed for 10 min followed by centrifugation at 10,000 g for 5 min. Polar metabolites were derivatized in 2% (w/v) methoxyamine hydrochloride (Thermo Scientific) in pyridine and incubated at 37 °C for 60 min. Samples were then silylated with N-tertbutyldimethylsilyl-Nmethyltrifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylchlorosilane (tBDMS) (Regis Technologies) at 37 °C for 30-45 min. Polar derivatives were analyzed by GC-MS using a DB-35MS column (30 m × 0.25 mm i.d. × 0.25 μ m, Agilent J&W Scientific) installed in an Agilent 7890 A gas chromatograph (GC) interfaced with an Agilent 5975 C mass spectrometer (MS). The lower chloroform phase was dried and then derivitized to form fatty acid methyl esters(FAMES) via addition of 500 μ l 2% H 2 SO 4 in MeOH and incubation at 50 °C for 2 h. FAMES were extracted via addition of 100 μ l saturated salt solution and 500 μ l hexane and these were analyzed using a Select FAME column (100 m × 0.25 mm i.d.) installed in an Agilent 7890 A GC interfaced with an Agilent 5975 C MS using the following temperature program: 80 °C initial, increase by 20 °C/min to 170 °C, increase by 1 °C/min to 204 °C, then 20 °C/min to 250 °C and hold for 10 min. The percent isotopologue distribution of each fatty acid and polar metabolite was determined and corrected for natural abundance using in-house algorithms adapted from Fernandez et al. 55 . The metabolite ion fragments used are summarized in Supplementary Table 6 . Mole percent enrichment (MPE) was calculated via the following equation:
where n is the number of carbon atoms in the metabolite and M i is the relative abundance of the ith mass isotopologue. Molar enrichment was determined by multiplying the MPE by the abundance. YSI (yellow springs instrument) was used to quantify glucose, lactate, glutamine and glutamate in cell culture media.
Isotopomer spectral analysis. The contribution of oxPPP-derived NADPH to lipogenesis using the [3- 2 H]glucose tracer was determined via isotopomer spectral analysis (ISA) using INCA as previously described 7 . The ISA compares a measured fatty acid isotopomer distribution (determined by integrating metabolite ion fragments of fatty acids summarized in Supplementary Table 6 ) to one that is simulated using a reaction network for palmitate synthesis, whereby 14 NADPH molecules are consumed to form one palmitate molecule. Models were also generated for mmBCFA and OCFA synthesis, whereby 12 NADPH molecules are consumed to form one branched or odd chain fatty acid (Supplementary Tables 7  and 8 . The 95% confidence intervals for both parameters were estimated by evaluating the sensitivity of the sum of squared residuals between measured and simulated fatty acid mass isotopomer distributions to small flux variations.
GC-MS analysis of short-chain fatty acids.
Cecal content was weighed, and 2 μ l of water was added per mg of cecum. The sample was vortexed for 5 min and then centrifuged at 18,000 g for 5 min at 10 °C. The resultant cecal water was used for SCFA analysis, and the cecal pellet was dried overnight at 60 °C to obtain the dry weight.
For cecal SCFA quantification, 50 μ l of cecal water was added to a 2 ml eppendorf microcentrifuge tube, followed by 150 μ l water, 10 μ l 5 mM 2-ethylbutyrate, 30 μ l 10 mM sodium acetate-d3, 50 μ l 1-propanol and 50 μ l pyridine. The tube was placed on ice for 5 min, which was followed by addition of 100 μ l 1 M NaOH and 30 μ l methylchloroformate. The sample was then vortexed for 20 s followed by addition of 300 μ l MTBE and then vortexed for another 20 s followed by centrifugation at 10,000g for 5 min at 4 °C. 100 μ l of the upper phase was then transferred in duplicate to GC vials for analysis. Samples were analyzed by GC-MS using a DB-35MS column (30 m × 0.25 mm i.d. × 0.25 μ m, Agilent J&W Scientific) installed in an Agilent 7890B gas chromatograph (GC) interfaced with an Agilent 5977B mass spectrometer (MS) using the following temperature program: 50 °C initial with a hold time of 0.8 min, followed by an increase of 25 °C/ min to 120 °C and then an increase of 100 °C/min to 280 °C. Samples were injected using split mode (25 ml/min split flow), and the mass spectrometer was operated in scan mode between 50-150 AMU. Acetate was quantified from the internal acetate isotope standard and all other SCFAs were quantified from a standard curve extracted in parallel.
The isotopologue distributions of acetate and isovalerate were obtained via diethyl ether extraction and TBDMS derivatization of cecal water. Briefly, 10 μ l concentrated HCL (37%) and 1 ml Et 2 O was added to 100 μ l cecal water, which was followed by 10 min of vortexing and centrifugation at 18,000g at 15 °C for 5 min. The upper phase was added to a new tube and the Et 2 O extraction step was repeated. 250 μ l of the extract was aliquoted in triplicate to GC vials, and 25 μ l MTBSTFA + 1% tBDMS was added followed by incubation at room temperature for 1 h before GC-MS analysis with the following temperature program: 80 °C initial with a hold time of 0.8 min, followed by an increase of 15 °C/min to 150 °C with a hold time of 2 min, then an increase by 50 °C/min to 280 °C. Samples were injected using split mode (25 ml/min split flow) and the mass spectrometer was operated in scan mode between 50-500 AMU. H labeling of water from samples or standards was determined via deuterium acetone exchange. 5 μ l of sample or standard was reacted with 4 μ l of 10 N NaOH and 4 μ l of a 5% (v/v) solution of acetone in acetonitrile for 24 h. Acetone was extracted by the addition of 600 μ l chloroform and 0.5 g Na 2 SO 4 followed by vigorous mixing. 100 μ l of the chloroform was then transferred to a GC-MS vial. Acetone was measured using an Agilent DB-35MS column (30 m 3 0.25 mm i.d. × 0.25 μ m, Agilent J&W Scientific) installed in an Agilent 7890 A gas chromatograph (GC) interfaced with an Agilent 5975 C mass spectrometer (MS) with the following temperature program: 60 °C initial, increase by 20 °C/min to 100 °C, increase by 50 °C/min to 220 °C, and hold for 1 min. The split ratio was 40:1 with a helium flow of 1 ml/min. Acetone eluted at approximately 1.5 min. The mass spectrometer was operated in the electron impact mode (70 eV). The mass ions 58 and 59 were integrated and the percent M1 (m/z 59) calculated. Known standards were used to generate a standard curve and plasma percent enrichment was determined from this. All samples were analyzed in triplicate.
In vivo de novo lipogenesis calculations. Calculation of the fraction of newly synthesized fatty acids (FNS) was based on the method described by Lee et al. 57 , where FNS is described by the following equation:
Where ME is the average number of deuterium atoms incorporated per molecule (ME = 1 × m 1 + 2 × m 2 + 3 × m 3 … ), p is the deuterium enrichment in water and n is the maximum number of hydrogen atoms from water incorporated per molecule. N was determined using the equation:
As described by Lee et al. 57 , where q is the fraction of hydrogen atoms and p + q = 1. The molar amount of newly synthesized fatty acids (MNS) was determined by: MNS = FNS × total fatty acid amount (nmoles/mg tissue).
LC-MS lipidomic analysis.
Lipid extraction was carried out using a Folch-based methanol/chloroform/saline extraction at a ratio of 1:2:1 with the inclusion of C12:0 dodecylglycerol and hexadecanoic acid-d 31 as internal standards. The methanol phase was washed a second time with chloroform after addition of 1 μ l formic acid. Metabolite separation was achieved with a Luna reverse-phase C5 column (50 × 4.6 mm, with 5-μ m-diameter particles; Phenomenex). Mobile phase A was composed of a 95:5 ratio of water:methanol, and mobile phase B consisted of isopropanol, methanol, and water in a 60:35:5 ratio. Solvent modifiers 0.1% formic acid with 5 mM ammonium formate and 0.1% ammonium hydroxide were used to assist ion formation and to improve the LC resolution in both positive and negative ionization modes, respectively. The flow rate for each run started at 0.1 ml/min for 5 min to alleviate backpressure associated with injecting chloroform.
The gradient started at 0% B and increased linearly to 100% B over the course of 45 min with a flow rate of 0.4 ml/min, followed by an isocratic gradient of 100% B for 17 min at 0.5 ml/min before equilibrating for 8 min at 0% B with a flow rate of 0.5 ml/min. MS analysis was performed with an electrospray ionization (ESI) source on an Agilent 6430 QQQ LC-MS/MS. The capillary voltage was set to 3.0 kV, and the fragmentor voltage was set to 100 V. The drying gas temperature was 350 °C, the drying gas flow rate was 10 L/min, and the nebulizer pressure was 35 psi. Representative lipids were quantified by SRM of the transition from precursor to product ions at associated optimized collision energies as previously described 58 . Briefly, for the SRM transitions in which the transition of parent masses to the loss of the headgroup (for example, loss of phosphocholine from phosphatidylcholine) is monitored, the acyl chain specificities were determined from previously described procedures 58 . For phospholipids such as PCs and PEs, the fatty acid acyl chain composition was determined from phospholipids using a mobile phase containing both ammonium hydroxide and formic acid and the fatty acid fragmentations were monitored from [M-H + HCO2H] m/z at 40 V collision energy in negative ionization mode. For other phospholipids such as PAs and PIs, the fatty acid fragmentations from [M-H] m/z at 40 V collision energy in negative ionization mode in mobile phase containing just ammonium hydroxide were monitored. The identifying ion and the M + 4 (mass increment of 4) ion of each lipid was monitored, and relative abundance was determined by integrating the area under the curve followed by normalization to internal standard values. Significant incorporation of [U 13 C]valine into lipids was determined by comparing the relative abundance of the M + 4 ion of each lipid species targeted in [U 13 C 5 ] valine traced cells versus cells that had no tracer added (no trace) via fold change differences and Student's t-test. Percentage enrichment of each lipid species was determined via: n/a Confirmed
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Sample size
For high fat and low fat dietary intervention, power analysis was carried out on changes in circulating fasting glucose levels using an alpha of 0.05 and a 1-beta of 0.95 in order to calculate the animals required.
Data exclusions no data was excluded
Replication all results were repeated at least 3 independent times with the exception of FASN KO where two independent infections were carried out. All attempts at replication were successful.
Randomization Mice were assigned to groups randomly.
Blinding
Blinding was not possible as the dietary intervention caused visible differences in mouse appearance.
Reporting for specific materials, systems and methods Mycoplasma contamination
Cell culture was tested for mycoplasma and confirmed negative.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
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Laboratory animals
Animal handling and care followed the NIH Guide for Care and Use of Laboratory Animals. The experimental protocols were approved by either the UCSD, Salk or UMMS Institutional Animal Care and Use Committee. C57BL/6J, ob/ob(B6.Cg-Lepob/J) and swiss webster mice were used in this study. All males were used with the exception of female C57BL/6J which were used for a male female comparison.
Wild animals
This study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
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Population characteristics
For the NAFLD study, all procedures were approved by the University of California-San Diego Human Research Protections Program. Subjects provided written informed consent, and Declaration of Helsinki protocols were followed. Subjects were carefully screened and excluded for liver diseases other than NAFLD and secondary causes of hepatic steatosis. Eight males and eight females were in the study group with an age and BMI range of 31-70 and 27-40. Weight stable obese subjects undergoing elective laparoscopic gastric bypass via Roux-en-Y for the treatment of obesity were recruited for the study to provide material for pre-adipocyte isolation and skeletal muscle biopsie. Both human skeletal muscle biopsies and material for pre-adipocyte isolation were obtained with approval from the University of California San Diego's Committee on Human Investigation and VA San Diego Medical Center's Institutional Review Board. All donors provided informed written consent after listening to an explanation of the protocol and the study complied with all relevant regulations.
Recruitment
Subjects were recruited while undergoing diagnostic liver biopsy for suspected NAFLD. Subjects were recuited for pre-adipocyte isolation and muscle biopsie while undergoing elective laparoscopic gastric bypass via Roux-en-Y for the treatment of obesity.
